Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer (BEVARTHRALGIA2)

University Hospital, Lille

Status: Completed

Conditions: Arthralgia

Study type: Observational

Funder types: Other

Identifiers

NCT03455907

2017-A03012-51 (Other Identifier)

2017_50

Details and patient eligibility

About

Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers.

The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.

Enrollment: 71 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy
• Male or female (aged ≥18 years old)
• Performance Status (PS) between 0 and 2
• Expected life> 3 months
• Ability to answer a self-questionnaire
• Obtaining the non-opposition of patient participation

Exclusion criteria

• Pregnant or lactating woman
• Rapid evolution of neoplastic pathology
• Major cognitive disorders that do not allow filling of the self-questionnaire
• Impossibility to submit to medical monitoring for social, psychological or geographical reasons
• Patients under guardianship or curatorship

Trial design

71 participants in 1 patient group

Patients

Description:

patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab